Related Experiment Video

Updated: Jun 24, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Histone deacetylase inhibitors as anti-neoplastic agents

Nicolas Batty1, Gabriel G Malouf, Jean Pierre J Issa

  • 1Department of Leukemia, MD Anderson Cancer Center, Unit 428, Houston, TX 77030, USA.

Cancer Letters
|April 7, 2009
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise in treating certain cancers by altering protein acetylation and gene expression. While effective in some blood cancers, their role in solid tumors and combination therapies requires further investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Histone deacetylase inhibitors (HDACIs) are a novel drug class targeting protein acetylation.
  • HDACIs modulate chromatin structure, gene transcription, and cellular pathways, including cell death signaling in cancer.

Purpose of the Study:

  • To review recent basic and clinical data on the anti-neoplastic role of HDACIs.
  • To highlight the mechanisms of action and clinical efficacy of HDACIs in various cancers.

Main Methods:

  • Review of existing literature on HDACIs.
  • Analysis of in vitro and in vivo experimental models of cancer.
  • Examination of data from Phase I/II clinical trials of HDACIs.

Main Results:

  • HDACIs demonstrate anti-neoplastic activity in vitro across various cancer models.
  • Clinical trials show substantial activity in cutaneous T cell lymphoma (CTCL) and preliminary activity in Hodgkin's disease.
  • Modest activity observed in myeloid neoplasms, with rare responses in solid tumors.

Conclusions:

  • HDACIs represent a promising targeted therapy for specific cancers, particularly hematological malignancies.
  • Combination therapies involving HDACIs with chemotherapy, radiation, or DNA methylation inhibitors are under investigation for enhanced efficacy.
  • Further research is needed to elucidate mechanisms of cytotoxicity and expand the application of HDACIs in solid tumors.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Analysis of Histone Antibody Specificity with Peptide Microarrays09:47

Analysis of Histone Antibody Specificity with Peptide Microarrays

Published on: August 1, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...